A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-s

StephenW

Scand J Infect Dis. 2011 Sep 21. [Epub ahead of print]

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates
HBcAg-specific T cells and preS1-specific antibodies.

Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA,
Frelin L.

Source

Department of Laboratory Medicine, Division of Clinical Microbiology,
Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm
, Sweden.

Abstract

Abstract
A major problem in chronic hepatitis B virus (HBV) infection is
that treatment with specific antivirals is life-long since they rarely
induce a sustained response. An attractive option is therefore to combine
antiviral therapy with some type of immune stimulator, such as a
therapeutic vaccine. Several lines of evidence suggest that a key target
for the cellular immune response is the HBV core antigen (HBcAg). However,
it may also be of advantage to simultaneously improve the neutralizing
antibody response to the surface (S) region of HBV. We therefore generated
chimeric HBcAg particles expressing preS1 residues 1-42 at the tip of the
spike region. We could show that this chimeric HBcAg-preS1 protein primed
both HBcAg-specific T cells and antibodies to preS1. This strongly suggests
that this may be a viable approach to develop an effective bi-functional
therapeutic vaccine as an add-on for the treatment of chronic HBV
infections.

StephenW

[谷歌翻译是不是100％正确，仅供参考使用。]

双向功能的B型肝炎病毒核心抗原（HBcAg的）嵌合体的激活
HBcAg特异性T细胞和前S1特异性抗体。

马利克红外，Sällberg拉赫曼中号，陈阿，一个黄铜，阿伦G，M，库雷希司法机构政务长，
Frelin L。

来源

检验科，临床微生物科，
卡罗林斯卡研究所，斯德哥尔摩卡罗林斯卡大学医院呼丁格
，瑞典。

摘要

摘要在慢性乙型肝炎病毒（HBV）感染的主要问题是
与特定的抗病毒药物治疗是终身的，因为他们很少
诱发的持续反应。一个有吸引力的选择，因此结合
一些免疫刺激类型的抗病毒治疗，如
治疗性疫苗。几行的证据表明，一个关键的目标
细胞免疫反应，是乙肝病毒核心抗原（HBcAg的）。然而，
它也可能是优势，同时提高中和
抗体反应（S）的乙肝病毒表面区域。因此，我们生成
嵌合HBcAg的颗粒，表示针尖前S1残留1-42
穗地区。我们可以表明，此嵌合HBcAg的前S1蛋白催芽
HBcAg特异性T细胞和抗体，前S1。这有力地表明
这可能是一种可行的方法，建立一个有效的双向功能
作为一个附加的治疗慢性乙肝治疗性疫苗
感染。